Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Neurotech Pharmaceuticals.

    Client Virtual Booth

    NEUROTECH PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Neurotech Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    900 Highland Corporate Drive Building 1 Cumberland, RI 02864
    Telephone
    Telephone
    401-333-3880
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neurotechpharmaceuticals.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Neurotech Receives Priority Review for NT-501 as Treatment for MacTel Type 2

    Details:

    NT-501 (revakinagene taroretcel) leverages is a gene therapy which delivers CNTF through an ocular implant, it is designed for the treatment of chronic retinal diseases, such as MacTel.


    Lead Product(s): Revakinagene Taroretcel

    Therapeutic Area: Rare Diseases and Disorders Product Name: NT-501

    Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 20, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Neurotech Pharmaceuticals, Inc. Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2

    Details:

    Designed to be implanted into the vitreous cavity of the eye, the investigational Ciliary Neurotrophic Factor(Renexus) implant is a tiny hollow cylindrical membrane which encapsulates human epithelial cells genetically engineered to produce CNTF continuously.


    Lead Product(s): Ciliary Neurotrophic Factor

    Therapeutic Area: Ophthalmology Product Name: Renexus

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 02, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    farmak-a-s-m-2024-08-26

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search